Skip to main content
. 2009 Nov;1(3):183–205. doi: 10.1177/1758834009349119

Figure 3.

Figure 3.

(a) Interferon-α (IFN) with placebo (black line) versus IFN with bevacizumab (purple line) in untreated patients with recurrent or advanced renal cell carcinoma – AVOREN Trial – progression-free survival [Escudier et al. 2007c]. With permission, The Lancet, (b) Interferon-α (IFN) alone (black line) and with bevacizumab (purple line), in untreated patients with recurrent or advanced renal cell carcinoma – CALGB Trial 90206 – progression-free survival [Rini et al. 2008]. With permission, American Society for Clinical Oncology.